Home > Insider Trading > Filing (0001225208-15-020609)

Filing Details

Accession Number:: 0001225208-15-020609
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-09 20:09:25
Reporting Period:: 2015-11-05

Filing Date:: 2015-11-09
Accepted Time:: 2015-11-09 20:09:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1262104	Mei Pharma Inc.	MEIP	Pharmaceutical Preparations (2834)	510407811

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1565020	Vivo Ventures Vii, Llc	575 High Street, Suite 201 Palo Alto CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-11-05	225,660	$1.91	3,328,017	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-11-06	7,560	$1.85	3,320,457	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-11-09	157,352	$1.75	3,163,105	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Includes 3,257,032 shares held of record by Vivo Ventures Fund VII, L.P., and 70,985 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. (together, the "Vivo VII Funds"). Vivo Ventures VII, LLC (the "Vivo VII GP"), as the sole general partner of both of the Vivo VII Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo VII Funds. Vivo VII GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Includes 3,249,633 shares held of record by Vivo Ventures Fund VII, L.P., and 70,824 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. (together, the "Vivo VII Funds"). Vivo Ventures VII, LLC (the "Vivo VII GP"), as the sole general partner of both of the Vivo VII Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo VII Funds. Vivo VII GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Includes 3,095,637 shares held of record by Vivo Ventures Fund VII, L.P., and 67,468 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. (together, the "Vivo VII Funds"). Vivo Ventures VII, LLC (the "Vivo VII GP"), as the sole general partner of both of the Vivo VII Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo VII Funds. Vivo VII GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.